Sedative effects of low-dose risperidone in GAD patients and risk of drug interactions [2]

Journal of Clinical Psychiatry

Volumn 67, Issue 8, 2006, Pages 1307-1308

  Kopecek, Miloslav ^a   Mohr, Pavel ^a   Novak, Tomas ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450; FLUOXETINE; RISPERIDONE; SERTRALINE;

CLINICAL FEATURE; DRUG METABOLISM; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; LETTER; PRIORITY JOURNAL; SCORING SYSTEM; SEDATION; SOMNOLENCE; STATISTICAL ANALYSIS;

EID: 33748961994     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0821b     Document Type: Letter

References (5)

1. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005;66:1321-1325
2. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22:419-423
3. Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005;25:226-229
4. Spina E, D'Arrigo C, Migliardi G, et al. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 2004;26:386-390
5. Benazzi F. Gynecomastia with risperidone-fluoxetine combination. Pharmacopsychiatry 1999;32:41